Cell Mol Neurobiol 42 , 25932610 (2022)
Overall, 80% of people who got the oral drug reported gastrointestinal problems, which were described as mild to moderate, compared with 46% of people in the placebo group
In the phase 2 obesity trial, these heart-rate changes were reported as peaking during the study and then declining later
doi: 10.1126/science.aar3318 164
The underlying mechanisms for increased HR remain to be fully elucidated, but may be related to a direct GLP-1 receptor effect on myocytes in the sinoatrial node of the human heart and/or stimulation of the sympathetic nervous system
We bring BPC-157 Therapy to homes, offices, and hotels across San Antonio and nearby areas